Gene therapy for Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Denyer, Rachel ^a,b   Douglas, Michael R ^b,c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; ANTIPARKINSON AGENT; APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; LENTIVIRUS VECTOR; LEVODOPA; NANOPARTICLE; NEUROTENSIN; NEURTURIN; OXIDOPAMINE; PARKIN; PARVOVIRUS VECTOR; PROSAVIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADJUVANT THERAPY; BASAL GANGLION; CANAVAN DISEASE; CAUSE OF DEATH; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC TRANSDUCTION; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; LENTIVIRINAE; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PUTAMEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC PROCEDURE; SUBTHALAMIC NUCLEUS; SYMPTOM; TRANSGENE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

EID: 84859735330     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/757305     Document Type: Review

References (104)

1. Twelves D., Perkins K. S. M., Counsell C., Systematic review of incidence studies of Parkinson's disease Movement Disorders 2003 18 1 19 31 (Pubitemid 36150204)
2. Brown P., Oliviero A., Mazzone P., Insola A., Tonali P., Di Lazzaro V., Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease Journal of Neuroscience 2001 21 3 1033 1038 (Pubitemid 32163143)
3. Wichmann T., DeLong M. R., Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder Annals of the New York Academy of Sciences 2003 991 199 213 (Pubitemid 36793815)
4. Alvarez L., Macias R., Guridi J., Lopez G., Alvarez E., Maragoto C., Teijeiro J., Torres A., Pavon N., Rodriguez-Oroz M. C., Ochoa L., Hetherington H., Juncos J., DeLong M. R., Obeso J. A., Dorsal subthalamotomy for Parkinson's disease Movement Disorders 2001 16 1 72 78 (Pubitemid 36041116)
5. Su P. C., Tseng H. M., Liu H. M., Yen R. F., Liou H. H., Treatment of advanced Parkinson's disease by subthalamotomy: one-year results Movement Disorders 2003 18 5 531 538 (Pubitemid 36656537)
6. Benabid A. L., Pollak P., Gao D., Hoffmann D., Limousin P., Gay E., Payen I., Benazzouz A., Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders Journal of Neurosurgery 1996 84 2 203 214 (Pubitemid 26039470)
7. Obeso J. A., Olanow C. W., Rodriguez-Oroz M. C., Krack P., Kumar R., Lang A. E., Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease New England Journal of Medicine 2001 345 13 956 963
8. Levy R., Lang A. E., Dostrovsky J. O., Pahapill P., Romas J., Saint-Cyr J., Hutchison W. D., Lozano A. M., Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms Brain 2001 124 10 2105 2118 (Pubitemid 32945907)
9. Fahn S., Levodopa in the treatment of Parkinson's disease Journal of Neural Transmission 2006 71 1 15 (Pubitemid 351412101)
10. Parkinson Study Group, Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomised controlled trial Journal of the American Medical Association 2000 284 15 1931 1938
11. Kordower J. H., Emborg M. E., Bloch J., Ma S. Y., Chu Y., Leventhal L., McBride J., Chen E. Y., Palfi S., Roitberg B. Z., Brown W. D., Holden J. E., Pyzalski R., Taylor M. D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P., Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease Science 2000 290 5492 767 773
12. Marks W. J. Jr. , Bartus R. T., Siffert J., Davis C. S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Simpson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P. A., Larson P. S., Ostrem J. L., Nutt J., Kieburtz K., Kordower J. H., Olanow C. W., Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial The Lancet Neurology 2010 9 12 1164 1172
13. Eberling J. L., Jagust W. J., Christine C. W., Starr P., Larson P., Bankiewicz K. S., Aminoff M. J., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980 1983
14. Azzouz M., Martin-Rendon E., Barber R. D., Mitrophanous K. A., Carter E. E., Rohll J. B., Kingsman S. M., Kingsman A. J., Mazarakis N. D., Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease Journal of Neuroscience 2002 22 23 10302 10312 (Pubitemid 35416868)
15. Chaudhuri K. R., Healy D. G., Schapira A. H. V., Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurology 2006 5 3 235 245 (Pubitemid 43238347)
16. Fox S. H., Brotchie J. M., Lang A. E., Non-dopaminergic treatments in development for Parkinson's disease The Lancet Neurology 2008 7 10 927 938
17. Huang R., Han L., Li J., Ren F., Ke W., Jiang C., Pei Y., Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles Journal of Gene Medicine 2009 11 9 754 763
18. Gonzalez-Barrios J. A., Lindahl M., Bannon M. J., Anaya-Martnez V., Flores G., Navarro-Quiroga I., Trudeau L. E., Aceves J., Martinez-Arguelles D. B., Garcia-Villegas R., Jiménez I., Segovia J., Martinez-Fong D., Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats Molecular Therapy 2006 14 6 857 865 (Pubitemid 44793642)
19. Xia C. F., Boado R. J., Zhang Y., Chu C., Pardridge W. M., Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter Journal of Gene Medicine 2008 10 3 306 315 (Pubitemid 351359643)
20. Srivastava A., Lusby E. W., Berns K. I., Nucleotide sequence and organization of the adeno-associated virus 2 genome Journal of Virology 1983 45 2 555 564 (Pubitemid 13225420)
21. Schnepp B. C., Clark K. R., Klemanski D. L., Pacak C. A., Johnson P. R., Genetic fate of recombinant adeno-associated virus vector genomes in muscle Journal of Virology 2003 77 6 3495 3504 (Pubitemid 36297269)
22. Mandel R. J., Burger C., Snyder R. O., Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production Experimental Neurology 2008 209 1 58 71
23. Muzyczka N., Use of adeno-associated virus as a general transduction vector for mammalian cells Current Topics in Microbiology and Immunology 1992 158 97 129
24. Gao G., Vandenberghe L. H., Alvira M. R., Lu Y., Calcedo R., Zhou X., Wilson J. M., Clades of adeno-associated viruses are widely disseminated in human tissues Journal of Virology 2004 78 12 6381 6388 (Pubitemid 38715936)
25. Fitzsimons H. L., Riban V., Bland R. J., Wendelken J. L., Sapan C. V., During M. J., Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat Journal of Gene Medicine 2010 12 4 385 398
26. Dodiya H. B., Bjorklund T., Stansell J. III, Mandel R. J., Kirik D., Kordower J. H., Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates Molecular Therapy 2010 18 3 579 587
27. Xue Y. Q., Ma B. F., Zhao L. R., Tatom J. B., Li B., Jiang L. X., Klein R. L., Duan W. M., AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease Gene Therapy 2010 17 1 83 94
28. Peden C. S., Burger C., Muzyczka N., Mandel R. J., Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain Journal of Virology 2004 78 12 6344 6359 (Pubitemid 38715933)
29. Sanftner L. M., Suzuki B. M., Doroudchi M. M., Feng L., McClelland A., Forsayeth J. R., Cunningham J., Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV Molecular Therapy 2004 9 3 403 409 (Pubitemid 38404529)
30. Lowenstein P. R., Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects Molecular Therapy 2004 9 6 771 774 (Pubitemid 38878123)
31. Monahan P. E., Jooss K., Sands M. S., Safety of adeno-associated virus gene therapy vectors: a current evaluation Expert Opinion on Drug Safety 2002 1 1 79 91
32. Tenenbaum L., Lehtonen E., Monahan P. E., Evaluation of risks related to the use of adeno-associated virus-based vectors Current Gene Therapy 2003 3 6 545 565
33. Samulski R. J., Chang L. S., Shenk T., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression Journal of Virology 1989 63 9 3822 3828 (Pubitemid 19205454)
34. Vigna E., Naldini L., Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy Journal of Gene Medicine 2000 2 5 308 316
35. Verma I. M., Weitzman M. D., Gene therapy: twenty-first century medicine Annual Review of Biochemistry 2005 74 711 738 (Pubitemid 40995522)
36. Naldini L., Blmer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M., Trono D., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 1996 272 5259 263 267 (Pubitemid 26119138)
37. Hioki H., Kameda H., Nakamura H., Okunomiya T., Ohira K., Nakamura K., Kuroda M., Furuta T., Kaneko T., Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters Gene Therapy 2007 14 11 872 882 (Pubitemid 46780070)
38. Jakobsson J., Lundberg C., Lentiviral vectors for use in the central nervous system Molecular Therapy 2006 13 3 484 493 (Pubitemid 43257616)
39. Zufferey R., Nagy D., Mandel R. J., Naldini L., Trono D., Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo Nature Biotechnology 1997 15 9 871 875
40. Zhao J., Lever A. M. L., Lentivirus-mediated gene expression Methods in Molecular Biology 2007 366 343 355 (Pubitemid 350183486)
41. Choi-Lundberg D. L., Lin Q., Chang Y. N., Chiang Y. L., Hay C. M., Mohajeri H., Davidson B. L., Bohn M. C., Dopaminergic neurons protected from degeneration by GDNF gene therapy Science 1997 275 5301 838 841 (Pubitemid 27074886)
42. Lynch J. P., Fishbein M., Echavarria M., Adenovirus Seminars in Respiratory and Critical Care Medicine 2011 32 4 494 511
43. Lowenstein P. R., Castro M. G., Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences Gene Therapy 2003 10 11 946 954 (Pubitemid 36722429)
44. Schiedner G., Morral N., Parks R. J., Wu Y., Koopmans S. C., Langston C., Graham F. L., Beaudet A. L., Kochanek S., Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nature Genetics 1998 18 2 180 183 (Pubitemid 28082470)
45. Lowenstein P. R., Thomas C. E., Umana P., Gerdes C. A., Verakis T., Boyer O., Tondeur S., Klatzmann D., Castro M. G., Lowenstein P. R., High-capacity, helper-dependent, gutless adenoviral vectors for gene transfer into brain Methods in Enzymology 2002 346, article no. 17 292 311 (Pubitemid 41103144)
46. Muruve D. A., The innate immune response to adenovirus vectors Human Gene Therapy 2004 15 12 1157 1166 (Pubitemid 40052429)
47. Kamen A., Henry O., Development and optimization of an adenovirus production process Journal of Gene Medicine 2004 6 supplement 1 S184 S192 (Pubitemid 40228027)
48. Carr D. J. J., Tomanek L., Herpes simplex virus and the chemokines that mediate the inflammation Current Topics in Microbiology and Immunology 2006 303 47 65
49. Fink D. J., Glorioso J. C., Engineering herpes simplex virus vectors for gene transfer to neurons Nature Medicine 1997 3 3 357 359 (Pubitemid 27112938)
50. Cao H., Zhang G. R., Wang X., Kong L., Geller A. I., Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles BMC Neuroscience 2008 10 9, article 37
51. Rasmussen M., Kong L., Zhang G. R., Liu M., Wang X., Szabo G., Curthoys N. P., Geller A. I., Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter Brain Research 2007 1144 1 19 32 (Pubitemid 46440832)
52. Samaniego L. A., Neiderhiser L., DeLuca N. A., Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins Journal of Virology 1998 72 4 3307 3320 (Pubitemid 28175576)
53. Lilley C. E., Branston R. H., Coffin R. S., Herpes simplex virus vectors for the nervous system Current Gene Therapy 2001 1 4 339 358
54. Oxford BioMedica, ProSavin. Oxford Biomedica, http://www.oxfordbiomedica. co.uk/page.asp?pageid=29
55. Jarraya B., Boulet S., Ralph G. S., Jan C., Bonvento G., Azzouz M., Miskin J. E., Shin M., Delzescaux T., Drouot X., Hérard A. S., Day D. M., Brouillet E., Kingsman S. M., Hantraye P., Mitrophanous K. A., Mazarakis N. D., Palfi S., Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia Science Translational Medicine 2009 1 2 2ra4
56. Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D., Squinto S. P., Lindsay R. M., BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra Nature 1991 350 6315 230 232 (Pubitemid 21912205)
57. Klein R. L., Lewis M. H., Muzyczka N., Meyer E. M., Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer Brain Research 1999 847 2 314 320
58. Bjrklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., Mandel R. J., Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model Brain Research 2000 886 1-2 82 98
59. Marks W. J. Jr. , Ostrem J. L., Verhagen L., Starr P. A., Larson P. S., Bakay R. A., Taylor R., Cahn-Weiner D. A., Stoessl A. J., Olanow C. W., Bartus R. T., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial The Lancet Neurology 2008 7 5 400 408
60. Christine C. W., Starr P. A., Larson P. S., Eberling J. L., Jagust W. J., Hawkins R. A., Vanbrocklin H. F., Wright J. F., Bankiewicz K. S., Aminoff M. J., Safety and tolerability of putaminal AADC gene therapy for Parkinson disease Neurology 2009 73 20 1662 1669
61. Kaplitt M. G., Feigin A., Tang C., Fitzsimons H. L., Mattis P., Lawlor P. A., Bland R. J., Young D., Strybing K., Eidelberg D., During M. J., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial The Lancet 2007 369 9579 2097 2105 (Pubitemid 46935946)
62. LeWitt P. A., Rezai A. R., Leehey M. A., Ojemann S. G., Flaherty A. W., Eskandar E. N., Kostyk S. K., Thomas K., Sarkar A., Siddiqui M. S., Tatter S. B., Schwalb J. M., Poston K. L., Henderson J. M., Kurlan R. M., Richard I. H., Van Meter L., Sapan C. V., During M. J., Kaplitt M. G., Feigin A., AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial The Lancet Neurology 2011 10 4 309 319
63. Amsterdam Molecular Therapeutics, AMT obtains license to amgens GDNF gene to develop treatment for Parkinsons disease with AMTs proprietary gene therapy platform. Amsterdam molecular therapeutics. September 2008, http://www. amtbiopharma.com/news/92/182/AMT-Obtains-License-to-Amgen-s-GDNF-Gene-to- Develop-Treatment-for-Parkinson-s-Disease-with-AMT-s-Proprietary-Gene-Therapy- Platform.html
64. Bankiewicz K. S., Eberling J. L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., Cunningham J., Budinger T. F., Harvey-White J., Convection-enhanced delivery of AAV vector in Parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach Experimental Neurology 2000 164 1 2 14 (Pubitemid 30490717)
65. Kitahama K., Ikemoto K., Jouvet A., Araneda S., Nagatsu I., Raynaud B., Nishimura A., Nishi K., Niwa S. I., Aromatic l-amino acid decarboxylase- immunoreactive structures in human midbrain, pons, and medulla Journal of Chemical Neuroanatomy 2009 38 2 130 140
66. Bankiewicz K. S., Forsayeth J., Eberling J. L., Sanchez-Pernaute R., Pivirotto P., Bringas J., Herscovitch P., Carson R. E., Eckelman W., Reutter B., Cunningham J., Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC Molecular Therapy 2006 14 4 564 570 (Pubitemid 44296090)
67. Hadaczek P., Eberling J. L., Pivirotto P., Bringas J., Forsayeth J., Bankiewicz K. S., Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC Molecular Therapy 2010 18 8 1458 1461
68. Hamani C., Saint-Cyr J. A., Fraser J., Kaplitt M., Lozano A. M., The subthalamic nucleus in the context of movement disorders Brain 2004 127 1 4 20 (Pubitemid 38055342)
69. Bergman H., Wichmann T., DeLong M. R., Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus Science 1990 249 4975 1436 1438
70. Bu D. F., Erlander M. G., Hitz B. C., Tillakaratne N. J. K., Kaufman D. L., Wagner-McPherson C. B., Evans G. A., Tobin A. J., Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene Proceedings of the National Academy of Sciences of the United States of America 1992 89 6 2115 2119
71. Erlander M. G., Tillakaratne N. J. K., Feldblum S., Patel N., Tobin A. J., Two genes encode distinct glutamate decarboxylases Neuron 1991 7 1 91 100
72. Feldblum S., Erlander M. G., Tobin A. J., Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles Journal of Neuroscience Research 1993 34 6 689 706 (Pubitemid 23150329)
73. Mi J., Chatterjee S., Wong K. K., Forbes C., Lawless G., Tobin A. J., Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines Journal of Neuroscience Research 1999 57 1 137 148 (Pubitemid 29293588)
74. Luo J., Kaplitt M. G., Fitzsimons H. L., Zuzga D. S., Liu Y., Oshinsky M. L., During M. J., Subthalamic GAD gene therapy in a Parkinson's disease rat model Science 2002 298 5592 425 429 (Pubitemid 35176353)
75. Lee B., Lee H., Nam Y. R., Oh J. H., Cho Y. H., Chang J. W., Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models Gene Therapy 2005 12 15 1215 1222 (Pubitemid 41136316)
76. Emborg M. E., Carbon M., Holden J. E., During M. J., Ma Y., Tang C., Moirano J., Fitzsimons H., Roitberg B. Z., Tuccar E., Roberts A., Kaplitt M. G., Eidelberg D., Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism Journal of Cerebral Blood Flow and Metabolism 2007 27 3 501 509
77. Lin L. F. H., Doherty D. H., Lile J. D., Bektesh S., Collins F., GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 1993 260 5111 1130 1132 (Pubitemid 23186789)
78. Tomac A., Lindqvist E., Lin L. F. H., gren S. O., Young D., Hoffer B. J., Olson L., Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo Nature 1995 373 6512 335 339
79. Gill S. S., Patel N. K., Hotton G. R., O'Sullivan K., McCarter R., Bunnage M., Brooks D. J., Svendsen C. N., Heywood P., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nature Medicine 2003 9 5 589 595 (Pubitemid 36597106)
80. Lang A. E., Gill S., Patel N. K., Lozano A., Nutt J. G., Penn R., Brooks D. J., Hotton G., Moro E., Heywood P., Brodsky M. A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V. G. F., Elias W. J., Laws E. R., Dhawan V., Stoessl A. J., Matcham J., Coffey R. J., Traub M., Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Annals of Neurology 2006 59 3 459 466 (Pubitemid 43358066)
81. Patel N. K., Bunnage M., Plaha P., Svendsen C. N., Heywood P., Gill S. S., Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Annals of Neurology 2005 57 2 298 302 (Pubitemid 40179870)
82. Slevin J. T., Gash D. M., Smith C. D., Gerhardt G. A., Kryscio R., Chebrolu H., Walton A., Wagner R., Young A. B., Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal Journal of Neurosurgery 2007 106 4 614 620 (Pubitemid 46536457)
83. Kotzbauer P. T., Lampe P. A., Heuckeroth R. O., Golden J. P., Creedon D. J., Johnson E. M., Milbrandt J., Neurturin, a relative of glial-cell-line- derived neurotrophic factor Nature 1996 384 6608 467 470 (Pubitemid 26414664)
84. Creedon D. J., Tansey M. G., Baloh R. H., Osborne P. A., Lampe P. A., Fahrner T. J., Heuckeroth R. O., Milbrandt J., Johnson E. M., Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons Proceedings of the National Academy of Sciences of the United States of America 1997 94 13 7018 7023 (Pubitemid 27281983)
85. Horger B. A., Nishimura M. C., Armanini M. P., Wang L. C., Poulsen K. T., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson E., Milbrandt J., Rosenthal A., Bjorklund A., Vandlen R. A., Hynes M. A., Phillips H. S., Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons Journal of Neuroscience 1998 18 13 4929 4937 (Pubitemid 28285401)
86. Kordower J. H., Herzog C. D., Dass B., Bakay R. A. E., Stansell J., Gasmi M., Bartus R. T., Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys Annals of Neurology 2006 60 6 706 715 (Pubitemid 46048488)
87. Herzog C. D., Dass B., Gasmi M., Bakay R., Stansell J. E., Tuszynski M., Bankiewicz K., Chen E. Y., Chu Y., Bishop K., Kordower J. H., Bartus R. T., Transgene expression, bioactivity, and safety of CERE-120 (AAV2-Neurturin) following delivery to the monkey striatum Molecular Therapy 2008 16 10 1737 1744
88. Herzog C. D., Brown L., Gammon D., Kruegel B., Lin R., Wilson A., Bolton A., Printz M., Gasmi M., Bishop K. M., Kordower J. H., Bartus R. T., Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease Neurosurgery 2009 64 4 602 612
89. Huddleston D. E., Factor S. A., Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for parkinson's disease Current Neurology and Neuroscience Reports 2011 11 4 345 348
90. Bartus R. T., Herzog C. D., Chu Y., Wilson A., Brown L., Siffert J., Johnson E. M., Olanow C. W., Mufson E. J., Kordower J. H., Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains Movement Disorders 2011 26 1 27 36
91. Douglas M. R., Lewthwaite A. J., Nicholl D. J., Genetics of Parkinson's disease and parkinsonism Expert Review of Neurotherapeutics 2007 7 6 657 666 (Pubitemid 46911615)
92. Yamada M., Mizuno Y., Mochizuki H., Parkin gene therapy for -synucleinopathy: a rat model of Parkinson's disease Human Gene Therapy 2005 16 2 262 270 (Pubitemid 40344217)
93. Lo Bianco C., Schneider B. L., Bauer M., Sajadi A., Brice A., Iwatsubo T., Aebischer P., Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an -synuclein rat model of Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2004 101 50 17510 17515 (Pubitemid 39657434)
94. Yasuda T., Miyachi S., Kitagawa R., Wada K., Nihira T., Ren Y. R., Hirai Y., Ageyama N., Terao K., Shimada T., Takada M., Mizuno Y., Mochizuki H., Neuronal specificity of -synuclein toxicity and effect of Parkin co-expression in primates Neuroscience 2007 144 2 743 753 (Pubitemid 44855304)
95. Yasuda T., Hayakawa H., Nihira T., Ren Y.-R., Nakata Y., Nagai M., Hattori N., Miyake K., Takada M., Shimada T., Mizuno Y., Mochizuki H., Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of parkinson disease Journal of Neuropathology and Experimental Neurology 2011 70 8 686 697
96. Guzman J. N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P. T., Surmeier D. J., Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 2010 468 7324 696 700
97. Paterna J. C., Leng A., Weber E., Feldon J., Beler H., DJ-1 and parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice Molecular Therapy 2007 15 4 698 704 (Pubitemid 46431989)
98. de Yigo-Mojado L., Martn-Ruz I., Sutherland J. D., Efficient Allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi PLoS ONE 2011 6 6, article e21352
99. Lewis T. B., Standaert D. G., Design of clinical trials of gene therapy in Parkinson disease Experimental Neurology 2008 209 1 41 47
100. Mandel R. J., CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease Current Opinion in Molecular Therapeutics 2010 12 2 240 247
101. McPhee S. W. J., Janson C. G., Li C., Samulski R. J., Camp A. S., Francis J., Shera D., Lioutermann L., Feely M., Freese A., Leone P., Immune responses to AAV in a phase I study for Canavan disease Journal of Gene Medicine 2006 8 5 577 588 (Pubitemid 43827251)
102. Kordower J. H., Olanow C. W., Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Experimental Neurology 2008 209 1 34 40
103. Somia N., Verma I. M., Gene therapy: trials and tribulations Nature Reviews Genetics 2000 1 2 91 99
104. Mueller C., Flotte T. R., Clinical gene therapy using recombinant adeno-associated virus vectors Gene Therapy 2008 15 11 858 863 (Pubitemid 351712619)